PT-141 (bremelanotide) is a synthetic peptide that stimulates melanocortin receptors in the brain to actively target and enhance sexual desire. Unlike medications like Viagra that focus strictly on blood flow mechanics, PT-141 operates on the central nervous system to help spark libido in both men and women
Benefits and uses
Â
PT-141 is used for sexual dysfunction in both men and women, with the strongest formal evidence in women:
-
Low sexual desire. The FDA-approved indication (as Vyleesi) is HSDD in premenopausal women — low desire that causes distress and is not attributable to another condition or medication.
-
Sexual arousal. Because it acts centrally, it is studied for arousal and desire rather than the mechanical, blood-flow effect of PDE5 inhibitors.
-
Use in men. PT-141 is used off-label and in research for low libido and sexual dysfunction in men, including cases where blood-flow-targeting drugs are insufficient.
The distinction from Viagra is the key point: PT-141 works through the brain, not the vascular system, which is why it addresses desire rather than only the physical mechanics of erection.
Common Side Effects & Risks
​
-
Nausea: Frequently reported and typically dose-dependent.
-
Flushing: Temporary warmth or redness in the face and upper chest.
-
Blood Pressure Changes: Can induce a temporary, mild spike in blood pressure and decrease in heart rate; unsafe for individuals with uncontrolled hypertension or cardiovascular disease
PT-141 (Bremelanotide)
Administration and Dosage
​
-
Delivery Method: Typically administered via a subcutaneous injection or specialized nasal formulation.
-
Timing: Usually taken on-demand roughly 45 minutes before anticipated sexual activity.
-
Adults—1.75 milligrams (mg) injected under the skin (starting dose 1mg, max 2 mg). Do not use more than one dose of this peptide within 24 hours. Do not use more than 8 doses per month.
-
Caution: Unregulated research-chemical versions found online lack quality control, precise dosing, and safety screening
References
Â
-
1. Kingsberg SA, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder." Obstet Gynecol. 2019;134(5):899-908.
-
2. Clayton AH, et al. "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial." Womens Health. 2016;12(3):325-337.
-
3. Safarinejad MR. "Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder." J Sex Med. 2008;5(3):798-814.
-
4. Diamond LE, et al. "An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141)." J Sex Med. 2006;3(4):628-638.
-
5. FDA. "Vyleesi (bremelanotide) prescribing information." 2019.